Risk factors for ovarian cancer: a case-control study. by Booth, M et al.
Booth, M; Beral, V; Smith, P (1989) Risk factors for ovarian cancer:
a case-control study. British journal of cancer, 60 (4). pp. 592-598.
ISSN 0007-0920 DOI: https://doi.org/10.1038/bjc.1989.320
Downloaded from: http://researchonline.lshtm.ac.uk/4651883/
DOI: 10.1038/bjc.1989.320
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
Br. J. Cancer (1989), 60, 592-598 © The Macmillan Press Ltd.,
Risk factors for ovarian cancer: a case-control study
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Summary A hospital-based case-control study of ovarian cancer was conducted in London and Oxford
between October 1978 and February 1983. Menstrual characteristics, reproductive and contraceptive history
and history of exposure to various environmental factors were compared between 235 women with his-
tologically diagnosed epithelial ovarian cancer and 451 controls. High gravidity, hysterectomy, female sterilisa-
tion and oral contraceptive use were associated with a reduced risk of ovarian cancer. Infertility and late age
at menopause were associated with an increase in risk. While these factors were related, they were each found
to be independently associated with ovarian cancer risk after adjusting for the effect of the other factors.
While results from recent case -control studies have con-
sistently shown that multiparity and oral contraceptive use
are associated with a reduced risk of ovarian cancer, the
association of the cancer with other reproductive, hormonal
and related factors such as age at menopause, history of
hysterectomy or use of oestrogen replacement therapy is less
clear. We have conducted a hospital-based case-control
study in London and Oxford which was designed to inves-
tigate the independent contributions of reproductive history
and contraceptive use to ovarian cancer risk. In particular, it
was planned to attempt to segregate out the effect on risk of
infertility from that of voluntary limitation of family size.
The association between ovarian cancer and other possible
aetiological agents was also examined.
Subjects and methods
Between October 1978 and February 1983 five interviewers
identified and questioned women with a diagnosis of ovarian
cancer and women selected as controls at 13 hospitals in
London and two in Oxford. A standard questionnaire was
used to obtain information on reproductive and menstrual
history and on exposure to various substances such as
exogenous oestrogens, cigarettes and talc. A month by month
record was made of the specific contraceptive methods used
by each woman between the ages of 16 and 45 years, or, if
under 45 years, up to the time of diagnosis (cases) or inter-
view (controls). The methods were classified as sheaths,
diaphragms, intrauterine devices, oral contraceptives or
'other methods' (spermicides, rhythm and coitus interruptus).
Women who reported using a contraceptive diaphragm were
asked if they had stored it in talc. Also recorded were
months during which a woman was not using contraception
due to sexual abstinence, pregnancy, menopause or because
she or her partner had been sterilised. The other months
when a woman reported using no method of contraception
although sexually active have been classified as months of
'unprotected intercourse'. The total duration of use of each
contraceptive method, of any contraceptive method, of unp-
rotected intercourse and of pregnancy were computed for
each woman.
The study was confinied to women aged less than 65 years
whose diagnosis of ovarian cancer had been made within two
years of interview. A total of 280 cases were interviewed and
pathological specimens were histologically classified by Pro-
fessor C. Hudson and Dr M. Curling from St Bartholomews
Hospital. A total of 235 women with epithelial ovarian
cancer were included in the analyses. For these women, the
tumour type was described as serous in 101 (43%) cases,
mucinous in 38 (15%) cases, endometrioid in 52 (22%) cases
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and clear cell in 12 (5%) cases. Mixed and undifferentiated
types of epithelial tumours accounted for the remaining 32
(14%) cases. Excluded from the analyses were nine women
with a non-epithelial ovarian neoplasm, 11 with a primary
tumour in an unknown site outside the ovary, 21 with a
primary tumour in an unknown site although one consistent
with an ovarian origin, one with a benign tumour and three
for whom pathology material could not be obtained.
For each case it was planned to select two age-matched
controls from women being treated in the same hospital.
Women with bilateral oophorectomy were excluded from the
control group as were women admitted with conditions that
have been related to reproductive history or oral contracep-
tive use (all circulatory and gynaecological diseases, gallblad-
der and thyroid diseases, rheumatoid arthritis, malignant
disease of the breast, uterus and bladder, and melanoma).
It proved logistically impossible to select two age-matched
controls for each case from the same hospital and it was
decided merely to ensure that the age distribution of the
controls was approximately the same as that of the cases.
For 63 cases recruited from a London hospital where only
cancer patients are treated, controls were selected from other
London hospitals. For these reasons, the data were analysed
using an unmatched approach with adjustments being made
to relative risk estimates for age and socio-economic status.
A total of 451 controls have been included in the analyses.
The admission diagnoses for these patients were gastrointes-
tinal disease (105), bone or joint disease (70), respiratory
disease (39), renal or other urinary disease (35), neurological
disease (30), fractures or other injuries (28), skin or sub-
cutaneous tissue disease (17), malignant neoplasms of the
digestive organs (15) and bone or skin (2), benign neoplasms
of the digestive organs (4) respiratory system (4) and other
sites (8) and various other conditions and symptoms (94).
This final category included patients with haemorrhoids (15)
and those with symptoms relating to the respiratory system
(10), gastrointestinal tract (20) and urinary system (10).
Maximum likelihood estimates of relative risk (RR)
together with their 95% confidence interval (95% CI) and
tests for trend where appropriate were computed by multiple
logistic regression techniques (Breslow & Day, 1980) using
the GLIM statistical package (Baker & Nelder, 1978). All
relative risks have been adjusted for age in 5-year strata
(20-24, 25-29, . . . 60-64) and for social class in six
categories (1,II,JII non-manual, III manual, IV and V). Age
of the cases was taken as age at diagnosis of ovarian cancer
and of the controls as age at interview. Social class was based
on occupation (Office of Population Censuses and Surveys,
1970) using husband's occupation for ever married women
and own occupation for those who had never married. Other
relative risk adjustments and tests for trend have been made
with the exposures as continuous variables. When the data
were examined by place of interview (London or Oxford),
there were no notable differences in the risk estimates
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associated with the major variables of interest. The relative
risks have not, therefore, been stratified by place of interview.
The terms nulligravid and gravid have been used to denote,
respectively, women who have never knowingly conceived
and women who have had at least one pregnancy. Parity has
been defined as number of live and still births.
Results
The age distributions of the cases and controls are shown in
Table I. The average age of the cases was slightly higher than
that of the controls. There was an excess of cases in social
classes I, II, and III non-manual (58%) as compared to
controls (43%) (P = 0.05) and, because of this, all relative
risks have been adjusted for social class as well as age. Table
II shows the relative risks for ovarian cancer associated with
various aspects of pregnancy history. Nulligravid women had
a higher risk of ovarian cancer than gravid women
(RR = 1.7, 95% CI 1.1-2.6). The relative risks were elevated
both in nulligravid women who had been sexually active and
in those who had not, although significantly so only for the
sexually active. Among those who had ever been pregnant,
the relative risks decreased as the number of pregnancies
increased, (X2 (trend) = 4.3, P <0.05). Similarly, among
parous women, the higher the parity the lower the relative
risks (X2 (trend) = 3.9, P <0.05). After adjusting for parity,
the relative risks associated with successive numbers of
incomplete pregnancies (spontaneous and induced abortions)
also decreased although the trend was not statistically
significant (X2 (trend) = 0.5). Women having their first preg-
nancy after the age of 35 years had a significantly higher risk
of ovarian cancer than women with a first pregnancy before
the age of 20 years. Their risk was also higher than that for
nulligravid women. There was, however, no marked nor
significant trend of increasing risk the later the age at first
pregnancy (X2 (trend) = 1.0). Analyses by age at first livebirth
gave similar findings. After adjustment for number of livebir-
ths, women who had breastfed for more than two years in
total had over three times the risk of ovarian cancer com-
pared to women who had never breastfed (P < 0.05) but
overall, there was no significant trend the longer the duration
of lactation.
Analyses of infertility and subfertility as risk factors for
ovarian cancer were restricted to the 213 (91 %) cases and 240
(93%) controls who reported that they had ever been sexually
active. Among these women, 30 (14%) with ovarian cancer and
34 (8%) controls reported, when so questioned, that they had
had problems in becoming pregnant and, of these, 16 cases and
12 controls had never conceived. Analysis of the data on
contraceptive use suggested that there were other women who
might have been infertile or subfertile. Although sexually active,
they had used contraception infrequently or not at all and had
had few or no pregnancies. For all women who had ever been
sexually active, the risk of ovarian cancer increased with
increasing duration of unprotected intercourse after adjustment
for gravidity (X2 (trend) = 10.2, P <0.01). The effect was most
marked among nulligravid women who reported more than 10
years of unprotected intercourse. Their risk was over six times
that of nulligravid women who reported less than three months
of unprotected intercourse (Table III). Among gravid women,
those reporting over 10 years of unprotected intercourse had a
higher risk than other gravid women. There was no significant
trend in risk associated with the duration of use of any
Table I Age distribution and average age of cases and controls
Age (years) Cases (%) Controls (%)
20-34 13 (5.5) 33 (7.3)
35-44 27 (11.5) 75 (16.6)
45-54 87 (37.0) 156 (34.6)
55-64 108 (46.0) 187 (41.5)
Total 235 451
Average age (years) 52.4 51.4
Table II Relative risks for ovarian cancer associated with pregnancy
history
Variable Cases Controls RR (95% CI)
Gravidityb
Gravid
Nulligravid
Nulligravid and ever
sexually active
Nulligravid and never
sexually active
Number of pregnancies
0
2
3
4
Estimated reduction in relative
associated with each pregnancq
Parityb
0
2
3
4
Estimated reduction in relative risk
associated with each birth
No. of incomplete preg-
nanciesb.c
0
2
176 376 1.Oa
59 74 1.7 (1.1 -2.6)
37 44 1.9 (1.1-3.1)
22 30 1.5 (0.8-2.6)
59 74 1.Oa
43 71 0.8 (0.4-1.3)
63 107 0.7 (0.4-1.1)
37 98 0.5 (0.3-0.8)
13 41 0.4 (0.2-0.8)
20 59 0.4 (0.2-0.8)
x2 for trend = 4.3 P<0.05
(gravid women only)
risk 0.86 (0.78-0.94)
y
66 87 I.Oa
48 84 0.7 (0.4-
61 127 0.6 (0.4-
40 88 0.6 (0.3-
12 30 0.5 (0.2-
8 34 0.3 (0.1-
x2 for trend = 3.9 P<0.05
(parous women only)
1.2)
1.0)
-1.0)
1.0)
-0.7)
0.84 (0.75-0.94)
185 330
39 83
7 18
4 19
X2
Estimated reduction in relative
risk associated with each incomplete pregnancy
Age at first pregnancy
(years)d
15- 19
20 -24
25 -29
30-34
35
Nulligravid
Months of lactatione
None
<6
7-12
13- 18
19-24
,25
26
73
49
17
9
59
x2 for trend =
l
.02
0.9
0.7
0.6
= 0.5
(0.6-
(0.3-
(0.2-
-1.4)
-1.8)
-1.7)
0.92 (0.75-1.13)
65 1.02
182 0.9 (0.5- 1.5)
96 1.2 (0.7-2.2)
29 1.2 (0.8-2.7)
4 4.1 (1.1
-15.1)
74 2.0 (1.1
-3.7)
1.0 (gravid women only)
44 107 1.0o
66 124 1.3
29 80 0.9
13 29 1.2
5 7 2.1
12 15 3.4
x2 for trend = 1.8
(0.8-
(0.5-
(0.5-
(0.7-
(1.1
-2.2)
-1.6)
-2.5)
-6.7)
-10.8)
All relative risks adjusted for age and social class. 'Reference
bcategory. Data missing for I control. cRelative risks adjusted for parity.
dData missing for 2 cases and 1 control. eWomen with livebirths only.
Relative risks adjusted for number of live births.
contraception (X2 (trend) = 1.2) although sexually active nulli-
gravid women who had never used any method ofcontraception
had about twice the risk of ovarian cancer compared to all other
sexually active women (Table IV).
Of the specific methods of contraception studied, ever having
used oral contraception and having been sterilised were
associated with a statistically significantly reduced risk of
ovarian cancer, while no method was associated with a
significantly elevated risk (Table V). As only three cases had
been sterilised it was not possible to assess whether age at
sterilisation influenced the risk of ovarian cancer. Table VI
shows detailed analyses of the relative risks associated with oral
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Table III Relative risks for ovarian cancer associated with duration of
unprotected intercourse by gravidity
Cases Controls RR (95% CI)
Nulligravid women
Duration of un-
protected intercourse (months)b
<,3
4-60 12 26 1.oa (0.4-6.5)
61-120 4 6 1.5 (0.1-7.8)
> 120 1 4 0.7 (2.1-20.4)
20 8 6.5
X2 for trend = 11.2 P<0.001
Gravid women
Duration of un-
protected intercourse (months)b
<,3
4-60 78 176 1.1 (0.5-2.4)
61-120 51 113 1.1 (0.5-2.6)
> 120 10 27 1.1 (0.4-3.2)
37 60 1.6 (0.7-4.0)
X2 for trend = 2.6
Sexually active women only. Relative risks adjusted for age and social
class. aReference category. bTime when sexually active and at risk of
pregnancy but using no contraception.
Table IV Relative risks for ovarian cancer associated with duration of
use of contraception by gravidity
Cases Controls RR (95% CI)
Nulligravid women
Duration of use of con-
traception
Never used 15
< 10 years 14
10-20 years 6
> 20 years 2
X2 for trend = 0.9
Gravid women
Duration of use of con-
traception
Never used 32
< 10 years 25
10-20 years 55
> 20 years 64
x2 for trend = 0.3
10
21
9
4
47
56
147
126
1.0"
0.5
0.5
0.4
0.4
0.3
0.4
0.5
(0.1 -1.7)
(0.1-2.5)
(0.1 -3.2)
(0.2-1.1)
(0. I - 1.0)
(0.1 -1.2)
(0.2-1.5)
Sexually active women only. Relative risks adjusted for age, social
class and duration of unprotected intercourse. aReference category.
Table V Relative risks for ovarian cancer associated with the use of
different methods of contraception
Method of contraception Cases Controls RR (95% CI)
Sheath Never used 108 205 l.0a
Ever used 105 215 1.1 (0.8-1.7)
Diaphragm Never used 178 329 1.Oa
Ever used 35 91 0.7 (0.4-1.1)
Intrauterine Never used 201 383 1.Oa
device Ever used 12 37 0.8 (0.4- 1.7)
Oral Never used 178 306 1.Oa
contraception Ever used 35 114 0.5 (0.3-0.9)
Partner with No 203 404 1.Oa
vasectomy Yes 10 16 2.1 (0.9-4.9)
Female No 210 375 lO.a
sterilisation Yes 3 45 0.2 (0.1 -0.6)
Other Never Used 156 292 1.oa
methodsb Ever used 57 128 1.1 (0.7 -1.7)
Sexually active women only. Relative risks adjusted for age, social
class, gravidity and duration of unprotected intercourse. aReference
category. bUse of spermicides, rhythm or coitus interruptus.
contraceptive use. The risks decreased as duration of use
increased although, among those who had ever used such
contraceptives, the trend was not significant (X2 (trend) = 1.2).
Whatever their age at first use, women who used oral contracep-
tives had a lower risk of ovarian cancer than those who had
never used them, the risk being lowest in those who had first
used oral contraceptives under the age of 25 years. The risk of
developing ovarian cancer did not increase as time since
discontinuing use increased. Women who had stopped using
oral contraceptives more than ten years previously had a
statistically significant reduced risk of 0.3 compared to women
who had never used them. Women both under the age and over
the age of 40 years had a reduced risk of ovarian cancer
associated with oral contraceptive use, but the reduction was
greater in the younger women. Gravid and nulligravid women
who had used oral contraceptives had a reduced risk of ovarian
cancer.
Table VII shows the relative risks associated with age at
menarche and age at natural menopause. There was no trend in
risk with age at menarche (X2 (trend) = 0.03). In contrast, risk
increased the later the age at natural menopause (X2 (trend) =
7. 1, P < 0.01). Women having their menopause at the age of 50
years or later had nearly three times the risk ofwomen who were
menopausal before the age of 45 years. The risks and trend
associated with age at menopause were similar irrespective of
whether they were adjusted for age in five year or one year strata.
Table VI Relative risks for ovarian cancer associated with oral
contraceptive (OC) use
Cases Controls RR (95% CI)
Duration of OC use
(years)
Never used
<5
5-10
>10
Age at first OC use
(years)
Never used
<25
25-29
30-34
B 35
Time since
discontinuing OC use
(years)
Never used
Current users
<5
5- 10
>10>I0~~
178 306 l.O"
24 70 0.6 (0.3-
10 29 0.6 (0.2-
1 15 0.1 (0.01
x2 for trend within users = 1.2
178 306 1.0"
6 39 0.1 (0.04 -
6 17 0.6 (0.2
11 27 0.7 (0.3
12 31 0.7 (0.4
2 for trend within users = 5.9, P <0.05
178 306
6 19
12 24
9 25
8 46
,2for trend within users
1.0"
0.5
0.8
0.8
0.3
= 2.6
Age (years)
<40
OC use
Never used 11 11 1.0
Ever used 9 35 0.2
40
OC use
Never used 167 295 1.0"
Ever used 26 79 0.7
Gravidity
Gravid womenb
OC use
Never used 149 280 1.0"
Ever used 27 96 0.5
(0.2
(0.4-
(0.3 -
(0.1
'1.0)
1.4)
1.0)
-0.5)
2.0)
1.6)
1.5)
1.5)
1.9)
1.9)
-0.7)
(0. 1 -0.9)
(0.4-- 1.2)
(0.3 -0.9)
Nulligravid women
OC use
Never used 29 26 1.0l
Ever used 8 18 0.3 (0.05 -2.8)
Sexually active women only. Relative risks adjusted for age, social
class, gravidity and duration of unprotected intercourse. aReference
category. bRelative risks adjusted for gravidity.
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Table VII Relative risks for ovarian cancer associated with age at
menarche and age at natural menopause
Cases Controls RR (95% CI)
Age at menarche
(years)b
>14 97 197 l.Oa
12- 13 89 185 0.9 (0.6- 1.3)
< 12 46 66 1.3 (0.8-2.1)
X2 for trend = 0.03
Age at natural
menopause (years)c
< 45 10 34 1.oa
45-49 47 77 2.0 (0.9-4.7)
>50 84 99 2.5 (1.1-5.8)
X2for trend =7.1 P <0.01
Relative risks adjusted for age and social class. aReference category.
bData on age at menarche missing for 3 cases and 3 controls. cData on
age at menopause missing for 2 cases and 1 control.
Women who reported hysterectomy, with or without unilateral
oophorectomy, had a much reduced risk (Table VIII). Since
there were only 10 women with ovarian cancer who had had a
hysterectomy it was not possible to assess the effect of age at
hysterectomy on ovarian cancer risk.
Total duration ofovulation was estimated as the months from
menarche to diagnosis (cases) or interview (controls), or to
menopause, whichever came first, minus the total months of
anovulation due to pregnancy and oral contraceptive use.
Women who reported a hysterectomy were excluded from these
analyses as it was unknown if or when they had stopped
ovulating. For all women combined, there was a strong trend of
increasing risk the longer the duration of ovulation (X2 (trend)
= 17.8, P <0.001) (Table IX). In separate analyses by
menopausal status, there was no significant effect of duration of
ovulation after adjustment for the 'anovulatory' factors used to
estimate that exposure, namely, months of pregnancy and oral
contraceptive use and age at menopause for post-menopausal
women and months of pregnancy and oral contraceptive use for
premenopausal women. Duration of ovulation is very sensitive
to age but the risks and trends were virtually unaffected when
adjusted for age in one year rather than five year strata.
Five (2%) cases and 29 (6%) controls reported having taken
hormone pills as a pregnancy test and five (2%) cases and 13
(3%) controls had been given hormones to prevent miscarriage.
For all post-menopausal women, there was a small but non-
significantly increased risk of ovarian cancer associated with
ever having recieved hormone replacement therapy (Table X).
The excess was confined to women who had reported a
hysterectomy who had an 1-fold risk. The cases did not report
more severe menopausal symptoms. Among the hormone
treated women with ovarian cancer, 23% had endometrioid or
clear cell tumours compared to 38% in the untreated women.
The reproductive and related factors found to be statistically
significantly related to ovarian cancer risk (gravidity, duration
of unprotected intercourse, use of oral contraception, having
been sterilised, age at natural menopause and having had a
hysterectomy) are not independent and we also computed the
relative risks associated with each factor after adjusting for the
others (Table XI). As sterilisation is often a consequence ofhigh
parity, the risks associated with gravidity were not adjusted for
sterilisation as this was considered to be overadjustment. In this
study, 40% of the sterilised women had five or more children
compared with 9% of the unsterilised women. Each of the
variables remained statistically significantly related to ovarian
cancer risk, suggesting that each may be independently
associated with the risk of developing ovarian cancer.
There was no significant difference between the percentage of
cases (53%) and controls (57%) who had ever smoked cigaret-
tes. No cases or controls reported having worked with asbestos.
No cases but three controls reported a radiation-induced
menopause.
Women who reported using talc more than once a week or
daily had higher risks of ovarian cancer than women who
reported less frequent use (Table XII). Although the relative risk
of 2.0 associated with weekly use was statistically significant
Table VIII Relative risks for ovarian cancer associated with reported
history of hysterectomy and/or unilateral oophorectomy
Cases Controls RR (95% CI)
Reported womb intact 220 370 1.Oa
Reported unilateral 5 9 0.9 (0.4-2.1)
oophorectomy by no
hysterectomy
Reported hysterectomy 8 62 0.2 (0.1-0.4)
but conserved ovaries
Reported hysterectomy 2 10 0.4 (0.1 -1.1)
and unilateral
oophorectomy
Relative risks adjusted for age and social class. aReference category.
Table IX Relative risks for ovarian cancer associated with duration of ovulation
Relative risks
Relative risks adjustedfor age,
adjustedfor age, social class,
Relative risks social class and duration of
Duration of adjustedfor age duration of anovulation and age
ovulation (years) Cases Controls and social class anovulation at menopause
All womenb
< 30 59 163 1.0a
30- 34 73 106 2.0
35 -39 68 92 2.0
>40 19 13 4.3
X2 for trend = 17.8 P < 0.001
Post-menopausal women
< 30 14 53 1.0 1.0a 1.0"
30-34 54 81 2.4 2.1 0.9
35 -39 58 72 2.4 1.9 0.6
>40 14 10 5.0 4.0 0.7
X2 for trend = 12.3 P <0.001 7.7P <0.01 0.5
Premenopausal women
< 30 45 110 1.0a 1.0a
30-34 19 25 1.5 1.1
35-39 10 20 1.3 0.9
> 40 5 3 3.2 1.9
X2 for trend = 4.4 P < 0.05 0.6
Women reporting a hysterectomy excluded: aReference category. bData missing for 6 cases and 4 controls. cTotal months of pregnancy and oral
contraceptive use.
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Table X Relative risks for ovarian cancer associated with the use of
hormone replacement therapy for menopausal symptoms
Cases Controls RR (95% CI)
All post-menopausal
women
Use of hormone
replacement therapy
No 122 249 1.oa
Yes 34 44 1.5 (0.9-2.6)
Women reporting
hysterectomy
Use of hormone
replacement therapy
No 5 62 1.0a
Yes 5 10 10.9 (1.7-69.0)
Post-menopausal
women other than
those reporting
hysterectomy
Use of hormone
replacement therapy
No 177 187 1.oa
Yes 29 34 1.2 (0.7 -2.3)
Post-menopausal women only. Relative risks adjusted for age and
social class. aReference category.
Table XI Relative risks associated with the factors found to be
significantly related to ovarian cancer
Factor RR (950% CI) X2 test for trend (1 d.f.)
Graviditybc
0 1.0a
1 0.8 (0.4 -1.5)
2 0.8 (0.4 -1.4)
3 0.6 (0.3 -1.1)
4 0.4 (0.2 -1.0)
, 5 0.5 (0.2 -1.0) 6.5 P<0.05
Unprotected
intercourse (months)b
<3 1.0a
4- 60 1.3 (0.8 -2.0)
61 -120 1.1 (0.5 -2.5)
> 120 1.9 (1.2 -3.2) 7.8 P <0.05
Oral contraceptive useb
Never used 1.oa
< S years 0.6 (0.3 -1.1)
6- 10 years 0.6 (0.3 -1.4)
> 10 years 0.1 (0.02 -1.1) 4.6 P < 0.05
Ever sterilizedb 0.2 (0.05 -0.6)*
Age at natural
menopaused
< 45 years 1.oa
45-49 years 1.9 (0.8 -4.5) 8.2 P <0.01
50 years 2.6 (1.1 -6.1)
Ever reported 0.2 (0.1 -0.5)*
hysterectomyb
The relative risks associated with each factor have been adjusted for
age, social class and all the other factors in the table. aReference
category. bSexually active women only. cRelative risks not adjusted for
sterilization, see text for details. dWomen reporting natural menopause
only. *P < 0.001.
Table XII Relative risks for ovarian cancer associated with reported
frequency of talc use in the genital area
Cases Controls RR (95% CI)
Reported frequency
of talc useb
Never 76 178 1.oa
Rarely 6 16 0.9 (0.3-2.4)
Monthly 7 24 0.7 (0.3-1.8)
Weekly 57 77 2.0 (1.3 -3.4)
Daily 71 139 1.3 (0.8- 1.9)
X2 for trend = 3.80, P = 0.05
Relative risks adjusted for age and social class. aReference category.bData missing for 18 (8%) cases and 17 (4%) controls as questions on
talc use introduced three months after study began.
(P = 0.007), there was no consistent trend of increasing risk
with increasing frequency of talc use (X2 (trend)= 3.80,
P = 0.05). There was no significant difference between the
percentages of cases (86%) and controls (81 %) who had used
and kept their diaphragm in talc.
Discussion
As in most previously reported studies (Booth & Beral, 1985)
we found that nulligravid women had an increased risk of
ovarian cancer and that risk decreased as the number of
pregnancies increased. We also found that the greater the
number of incomplete pregnancies the lower the risk,
although the trend was not significant. Most other studies
have not investigated if women of low gravidity have an
increased risk of ovarian cancer because of reduced fertility
or because of voluntary limitation of family size, although
Joly et al. (1974), McGowan et al. (1979) and Nasca et al.
(1984) found a higher risk in women who had tried to
conceive but had failed. Our findings also suggest that infer-
tility is a risk factor for ovarian cancer. Women who had not
conceived but had been sexually active for more than 10
years without using contraception had about six times the
risk of all other women. Approximately half these women
had undergone investigations for infertility. For only five
cases and one control was the cause of their infertility deter-
mined. Thus, it is not possible to assess whether this high risk
group had normal or impaired ovarian function. Subfertility
may also be associated with ovarian cancer. Gravid women
reporting over 10 years of unprotected intercourse had a
50% higher risk than other gravid women, but this increase
was not statistically significant.
Age at first pregnancy was not found to be associated with
ovarian cancer risk although women having a first pregnancy
after the age of 35 years had a higher risk compared to
women having a first pregnancy at earlier ages and to nullig-
ravid women. Since subfertility might be a risk factor for
ovarian cancer, the relative risks associated with age at first
pregnancy were also adjusted for duration of unprotected
intercourse. The raised risk for women with a first pregnancy
after 35 years persisted (RR = 3.9, 95% CI 1.1- 14.2). Results
from other studies regarding the risk for women having a
first child at relatively older ages are inconclusive, some
finding no association (Newhouse et al., 1977; Casagrande et
al., 1979; Cramer et al., 1983; Lesher et al., 1985), others an
increased risk (Joly et al., 1974; McGowan et al., 1979;
Hildreth et al., 1981; Franceschi et al., 1982). Only Frances-
chi et al. (1982) found the increased risk to be statistically
significant and independent of parity.
Overall, there was no association between use of any con-
traception and ovarian cancer. Of the specific methods
studied, female sterilisation and use of oral contraception
were associated with a significant reduction in risk and no
method was associated with a significant increase in risk. The
associations remained after adjusting for gravidity and dur-
ation of unprotected intercourse, the measure used to
indicate infertility. While few studies have examined the
association between female sterilisation and ovarian cancer,
the relation between oral contraceptives and ovarian cancer
has been demonstrated in many studies (Booth & Beral,
1985). Like others, we demonstrated that the longer oral
contraceptives had been used, the lower the risk. Our findings
also suggested that the earlier the age at first use the lower
the risk and that the protective effect of oral contraceptives
persists after their use is stopped.
It has been suggested that inhibition of ovulation, as
induced by pregnancy and oral contraceptives, is the factor
which protects against ovarian cancer (Fathalla, 1971). If so,
postpartum anovulation associated with lactation might also
be expected to be protective. We found no evidence that the
longer a woman had breastfed the lower her risk of ovarian
cancer. Indeed, the highest risk was found in those who had
breastfed longest. Results from other studies are contradic-
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tory (Cramer et al., 1983; Mori et al., 1984; Risch et al.,
1983; Cancer and Steroid Hormone Study, 1987).
Our finding that age at menarche was not associated with
risk is consistent with results from most other studies (Casa-
grande et al., 1979; McGowan et al., 1979; Hildreth et al.,
1981; Franceschi et al., 1982). Age at natural menopause,
however, was strongly related to risk. While Hildreth et al.
(1981), Franceschi et al. (1982) and Tzonou et al. (1984) also
demonstrated that the later the age at menopause the greater
the risk, other studies have found no association (West, 1966;
Newhouse et al., 1977; Annegers et al., 1979; McGowan et
al., 1979; Cramer et al., 1983).
A lower frequency of hysterectomy, of unilateral oophorec-
tomy, or of both among cases compared to controls has also
been reported from several other studies (Wynder et al.,
1969; Joly et al., 1974; Annegers et al., 1979; McGowan et
al., 1979; Franceschi et al., 1982; Cramer et al., 1983). As
these studies were case-control in design, there may have
been some misclassification of controls who, rather than
having a hysterectomy with ovarian conservation, actually
had a hysterectomy with bilateral oophorectomy. Another
explanation for the findings might be that if at hysterectomy
a woman's ovaries look diseased, it is likely that they are
removed. If the diseased ovaries were precancerous, those
women who might otherwise have developed ovarian cancer
do not. Following hysterectomy with ovarian conservation,
reduced ovarian function or ovarian failure occurs in a pro-
portion of women, due possibly to the blood supply to the
ovaries being compromised (Beavis et al., 1969; Ellsworth et
al., 1983). Female sterilisation was also associated with a low
risk of ovarian cancer. Neil et al. (1975) have suggested that
the menstrual disturbance that many women experience after
sterilisation may reflect changed ovarian function due to
damage to the vascular supply to the ovaries. If both
hysterectomy and female sterilisation can indirectly affect
ovarian function then both procedures could also influence
the risk of ovarian cancer.
Recent investigators have shown that the longer a woman
ovulates the greater her risk of ovarian cancer (Casagrande et
al., 1979; Hildreth et al., 1981; Franceschi et al., 1982; Wu et al.,
1988). We also found that risk increased the longer the duration
of ovulation. Duration of ovulation is, however, highly cor-
related with the 'anovulatory' factors used to estimate the
exposure. In an attempt to determine whether duration of
ovulation had an effect over and above that expressed by its
relation with these factors, the risks and trends were adjusted for
duration of anovulation due to pregnancy and oral contracep-
tive use and, where appropriate, for age at menopause. The
significance of the effect disappeared. We conclude that it is not
possible to determine from these data whether it is the above
factors which inhibit ovulation that prevent ovarian cancer,
whether repeated ovulations promote it, or whether a combina-
tion of both is acting.
Our finding of no overall relationship between hormone
replacement therapy and ovarian cancer supports those ofother
investigators (Newhouse et al., 1977; Hildreth et al., 1981; Weiss
et al., 1982). An increased risk associated with the therapy was
found among women who reported hysterectomy, but the
finding was based on very few cases and may have been due to
chance. We did not find an increased risk associated with
oestrogen therapy for any particular tumour types as suggested
by Cramer et al. (1981) and Weiss et al. (1982).
The evidence linking talc with ovarian cancer is controversial
(Anonymous, 1977; Roe, 1979; Longo & Young 1979; Cramer
et al., 1982; Hartge et al., 1983). In this study, women who
reported talc use in the genital area more than once a week or
daily had higher risks of ovarian cancer than women who used
talc less frequently. The women were not asked how long they
had been using talc. It is possible that because of their symptoms
or disease-related pelvic examinations, the frequency of current
talc use by the cases may not have reflected their frequency of
past use. Since these and other results (Cramer et al., 1982;
Hartge et al., 1983) are insufficient to reject an association,
further work is needed on the relation between genital use of talc
and ovarian cancer.
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